Butyrate Differentiates Permissiveness to Clostridioides difficile Infection and Influences Growth of Diverse C. difficile Isolates
Daniel A. Pensinger, Andrea T. Fisher, Horia A. Dobrila, William Van Treuren, Jackson O. Gardner, Steven K. Higginbottom, Matthew M. Carter, Benjamin Schumann, Carolyn R. Bertozzi, Victoria Anikst, Cody Martin, Elizabeth Robilotti, JoMay Chow, Rachael H. Buck, Lucy S. Tompkins, Justin L. Sonnenburg, Andrew J. Hryckowian
Abstract
Clostridioides difficile is a leading cause of infectious diarrhea in humans, and it imposes a tremendous burden on the health care system. Current treatments for C. difficile infection (CDI) include antibiotics and fecal microbiota transplant, which contribute to recurrent CDIs and face major regulatory hurdles, respectively. Therefore, there is an ongoing need to develop new ways to cope with CDI. Notably, a disrupted "dysbiotic" gut microbiota is the primary risk factor for CDI, but we incompletely understand how a healthy microbiota resists CDI. Here, we show that a specific molecule produced by the gut microbiota, butyrate, is negatively associated with C. difficile burdens in humans and in a mouse model of CDI and that butyrate impedes the growth of diverse C. difficile strains in pure culture. These findings help to build a foundation for designing alternative, possibly diet-based, strategies for mitigating CDI in humans.